Clinical significance of serum miR-25 in non-small-cell lung cancer

References

• Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–1740.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics. Cancer. 2014;64:9–29.
   Web of Science ®Google Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism Clin Exp. 2015;64:S16–S21.
   PubMed Web of Science ®Google Scholar
• Ramalingam P, Palanichamy JK, Singh A, et al. Biogenesis of intronic miRNAs located in clusters by independent transcription and alternative splicing. Rna. 2014;20:76–87.
   PubMed Web of Science ®Google Scholar
• Wang C, Li S, Xu J, et al. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway. Br J Biomed Sci. 2019;76:17–23.
   PubMed Web of Science ®Google Scholar
• Mehlich D, Garbicz F, Włodarski PK. The emerging roles of the polycistronic miR-106b∼25 cluster in cancer – a comprehensive review. Biomed Pharmacother. 2018;107:1183–1195.
   PubMed Web of Science ®Google Scholar
• Wahlquist C, Jeong D, Rojas-Muñoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 2014;508:531–535.
   PubMed Web of Science ®Google Scholar
• Chen B, Liu J, Qu J, et al. MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4. Tumour Biol. 2017;39:1010428317703841.
   Google Scholar
• Feng X, Jiang J, Shi S, et al. Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. Int J Oncol. 2016;49:2600–2610.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang N, Liu P, et al. MicroRNA-2 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014;5:7013–7026.
   PubMedGoogle Scholar
• Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012;55:465–475.
   PubMed Web of Science ®Google Scholar
• Feng S, Pan W, Jin Y, et al. MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol. 2014;35:12339–12344.
   PubMedGoogle Scholar
• Wu C, Li M, Hu C, et al. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41:1257–1266.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wu Y, Meng Q, et al. Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3. In Vitro Cell Dev Biol Anim. 2016;52:62–67.
   PubMed Web of Science ®Google Scholar
• He Z, Liu Y, Xiao B, et al. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. Biochem Biophys Res Commun. 2015;457:235–241.
   PubMed Web of Science ®Google Scholar
• Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PloS one. 2012;7:e41629.
   PubMed Web of Science ®Google Scholar
• Xu FX, Su YL, Zhang H, et al. Prognostic implications for high expression of MiR-25 in lung adenocarcinomas of female non-smokers. Asian Pac J Cancer Prev. 2014;15:1197–1203.
   PubMedGoogle Scholar
• Kim BH, Hong SW, Kim A, et al. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2013;107:505–510.
   PubMed Web of Science ®Google Scholar
• Wang P, Yang D, Zhang H, et al. Early detection of lung cancer in serum by a panel of MicroRNA biomarkers. Clin Lung Cancer. 2015;16:313–319.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.
   PubMed Web of Science ®Google Scholar
• Stieber P, Holdenrieder S. Lung cancer biomarkers – where we are and what we need. Cancer Biomark. 2010;6:221–224.
   PubMed Web of Science ®Google Scholar
• Pan J, Song G, Chen D, et al. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Mol Cell Proteomics. 2017;16:2069–2078.
   PubMed Web of Science ®Google Scholar
• Oyama T, Osaki T, Baba T, et al. Molecular genetic tumour markers in non-small cell lung cancer. Anticancer Res. 2005;25:1193–1196.
   PubMed Web of Science ®Google Scholar
• Molina R, Holdenrieder S, Auge JM, et al. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark. 2010;6:163–178.
   PubMed Web of Science ®Google Scholar
• Xing S, Zhu Y, Sun Y. Serum sMICA as biomarker in detection of non-small-cell lung carcinoma. Br J Biomed Sci. 2018;75:50–52.
   PubMed Web of Science ®Google Scholar
• Gemma A, Kusumoto M, Kurihara Y, et al. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC following treatment with crizotinib. J Thorac Oncol. 2019;14(4):672–682.
   PubMed Web of Science ®Google Scholar
• Poroyko V, Mirzapoiazova T, Nam A, et al. Exosomal miRNAs species in the blood of small cell and non-small cell lungcancer patients. Oncotarget. 2018;9:19793–19806.
   PubMedGoogle Scholar
• Jia J, Huang B, Zhuang Z, et al. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis. Int J Biol Markers. 2018;33:222–230.
   PubMed Web of Science ®Google Scholar
• Hughes NP, Xu L, Nielsen CH, et al. A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomark. 2018;22:333–344.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram KHR, Fard SS, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–10518.
   PubMed Web of Science ®Google Scholar
• Caiazza C, Mallardo M. The roles of miR-25 and its targeted genes in development of human cancer. Microrna. 2016;5:113–119.
   PubMedGoogle Scholar
• Niu Y, Wu Y, Huang J, et al. Identification of reference genes for circulating microRNA analysis in colorectal cancer. Sci Rep. 2016;6:35611.
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
   PubMed Web of Science ®Google Scholar